 This is an investigational study. Lenalidomide is FDA approved for the treatment of multiple myeloma MM and myelodysplastic syndrome MDS. Rituximab is FDA approved for the treatment of non-Hodgkins lymphoma and certain types of leukemia. Carfilzomib is FDA approved and commercially available for the treatment of certain types of MM. The combination of these drugs is investigational. 